Peripheral Arterial Disease Clinical Trials in Omaha, Nebraska

4 studies are recruiting for peripheral arterial disease in Omaha, Nebraska right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease

   Peripheral artery disease (PAD) is associated with elevated oxidative stress, and oxidative stress has been implicated as the cause of reduced endothelial reactivity in individuals with PAD. Endothelial function is important because the endothelium contributes to the dilation of arteries during exe…

   Stage

   EARLY_Phase 1

   Ages

   50 to 75

   Site

   University of Nebraska - Omaha, Omaha, Nebraska

   Run by

   University of Nebraska

   See if you can join NCT06319339 on ClinicalTrials.gov

2. MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology

   In our research, we are delving into whether taking MitoQ for six months can improve the symptoms and function of people diagnosed with peripheral artery disease, especially those who suffer from leg pain while walking, known as intermittent claudication. We will be checking if MitoQ helps people w…

   Stage

   Not phased

   Ages

   21 and older

   Site

   VA Medical Center, Omaha, Nebraska

   Run by

   University of Nebraska

   See if you can join NCT06409949 on ClinicalTrials.gov

3. SCS for Patient With Painful Diabetic Neuropathy and Peripheral Arterial Disease

   Peripheral arterial disease (PAD) affects over 230 million adults worldwide and is a highly morbid, costly, and disabling condition. Ischemic leg pain drives disability in PAD patients and results from oxygen supply-demand mismatch, autonomic dysfunction, and muscle breakdown. This leg pain, which …

   Stage

   Not phased

   Ages

   19 to 89

   Site

   University of Nebraska Medical Center, Omaha, Nebraska

   Run by

   University of Nebraska

   See if you can join NCT06480786 on ClinicalTrials.gov

4. Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis

   Peripheral artery disease (PAD) is a manifestation of atherosclerosis that produces progressive narrowing and occlusion of the arteries supplying the lower extremities. The most common clinical manifestation of PAD is claudication, i.e., a severe functional limitation identified as gait dysfunction…

   Stage

   Phase 4

   Ages

   18 to 90

   Site

   VA Medical Center, Omaha, Nebraska

   Run by

   University of Nebraska

   See if you can join NCT02842424 on ClinicalTrials.gov